3rd United States Schizophrenia Advisory Board Meeting

December 10, 1995
Caribe Hilton
San Juan, Puerto Rico
Faculty

NANCY C. ANDREASEN, MD, PhD
Director, Mental Health Clinical Research Center
Professor of Psychiatry
Department of Psychiatry
University of Iowa Hospitals and Clinics
Iowa City, Iowa

RICHARD L. BORISON, MD, PhD
Professor and Chairman
Department of Psychiatry and Health Behavior
School of Medicine
Medical College of Georgia
Augusta, Georgia

DANIEL E. CASEY, MD
Professor of Psychiatry
Oregon Health Sciences University
Chief, Psychiatry Research Unit
Department of Veterans Affairs Medical Center
Portland, Oregon

KENNETH L. DAVIS, MD
Professor and Chairman
Department of Psychiatry
Mount Sinai School of Medicine
New York, New York

WILLIAM M. GLAZER, MD
Associate Clinical Professor of Psychiatry
Yale University
School of Medicine
New Haven, Connecticut

JOHN M. KANE, MD
Professor of Psychiatry
Albert Einstein College of Medicine
Chairman, Department of Psychiatry
Hillside Hospital, Division of Long Island Jewish Medical Center
Glen Oaks, New York

STEPHEN R. MARDER, MD
Chief, Psychiatry Service
West Los Angeles VA Medical Center
Professor of Psychiatry and Vice Chairman
UCLA School of Medicine
Los Angeles, California

HERBERT Y. MELTZER, MD
Professor of Psychiatry
Case Western Reserve University
School of Medicine
Cleveland, Ohio

STEVEN G. POTKIN, MD
Professor
Department of Psychiatry and Human Behavior
University of California, Irvine
Orange, California

NINA R. SCHOOLER, PhD
Professor of Psychiatry
University of Pittsburgh
Director, Psychosis Research Program
Western Psychiatric Institute and Clinic
Pittsburgh, Pennsylvania

CAROL A. TAMMINGA, MD
Professor of Psychiatry
Chief, Inpatient Program
Maryland Psychiatric Research Center
School of Medicine
University of Maryland
Baltimore, Maryland

Core Project Team Members

CHARLES BEASLEY, JR, MD
Senior Clinical Research Physician

JIM LANCASTER
Director, Global CNS Business Unit

JOHN R. RICHARDS, RPH
Manager, Zyprexa Marketing Plans

TODD SANGER, PhD
Senior Statistician

WINSTON SATTERLEE, MD
Clinical Research Physician

GARY D. TOLLEFSON, MD, PhD
Vice President
Lilly Research Laboratories

PIERRE TRAN, MD
Clinical Research Physician
Eli Lilly and Company
SUNDAY, DECEMBER 10, 1995
CARIBE HILTON
SAN JUAN, PUERTO RICO

Agenda

12:00–1:00 PM  BUFFET LUNCH

1:00–2:00  HGAJ DATA PRESENTATION
Charles Beasley, Jr, MD

2:00–2:30  GROUP DISCUSSION

2:30–3:00  OVERVIEW OF THE INTEGRATED OLanzAPINE DATABASE
Gary D. Tollefsen, MD, PhD

3:00–3:15  COFFEE BREAK

3:15–4:30  ADVISORY COMMITTEE DISCUSSION
Gary D. Tollefsen, MD, PhD; Todd Sanger, PhD; Charles Beasley, Jr, MD;
Pierre Tran, MD; Winston Satterlee, MD

4:30–4:45  OLanzAPINE LABEL
Jim Lancaster

4:45–5:15  GROUP DISCUSSION
Jim Lancaster; John R. Richards, RPh

5:15–5:30  OVERVIEW OF THE 1996 CLINICAL PLAN
Gary D. Tollefsen, MD, PhD

5:30–6:00  GROUP DISCUSSION
Gary D. Tollefsen, MD, PhD; Charles Beasley, Jr, MD

6:00–6:15  CLOSING REMARKS

6:15–8:00  RECEPTION/LIGHT DINNER
February 4, 1994  13:43

To: HADLEY GARY R
    RICHARDS JOHN R
cc: DICKSON DENISE L
    JONES YVONNE N
    PERSUY JACQUELINE

Re: Off Label Studies in Olanzapine Life Plan

I just wanted to drop you two a note to ask you to seriously consider adding some off label studies into Life Plan. We all know that the off label segment is large, particularly in some countries. Also, we know from our work that there are some common off label uses across all countries -- agitation and anxiety probably at the top of the list, but there are several important ones.

Jacqueline Persuy and I discussed this on her recent visit. She believes these off label studies are essential to Olanzapines' success in France and obviously is very interested in getting them into our time line as soon as possible.

I would appreciate your feedback on this issue.

Regards,

Denise L. Dickson
HGAJ Study Report Documentation - Individual Marked Lab Abnormalities

Description: This binder contains output used to write the individual marked lab abnormalities section of the CRS (acute and double-blind extension) and also the one-page patient summaries for patients with abnormal labs in the open-label extension.

The following identifies which output was used for the corresponding CRS or OPPS:

Purple tab - Output 22 June 1995 was used for the acute study report and was run off the DBOLXI database. This output identifies all patients with 2 consecutive abnormal labs and/or abnormal at endpoint. Abnormals at endpoint does include patients who were abnormal at visit 8 and continued into the double-blind extension. This criteria is slightly different from the other CSR’s.

Blue tab - Output 1 June 1995 was used for the double-blind extension report.

Red tab - Output 14 May 1995 was used for the first acute report. This report was run off the acute database. However, this acute report was never finished due to the update of database that impacted the acute report.

2 purple tabs - Output 05 July 1995 was used for the OPPS for patients in the open-label extension phase.

John Krueger